CYAD-01

December 21, 2018December 21, 2018

Celyad’s Donor-derived CAR T-cell Therapy Begins Testing in Colorectal Cancer

News

A Phase 1 trial evaluating Celyad’s CYAD-101 — a donor-derived CAR T-cell product — to treat metastatic colorectal cancer has dosed its first patient, the company announced. The trial, called Allo-SHRINK ... Read more

November 20, 2018November 20, 2018

Celyad’s CAR T-Cell Therapy, CYAD-01, Showing Early Signs of Efficacy in Advanced Colorectal Cancer

News

CYAD-01 — Celyad‘s CAR T-cell product — is showing promise as a treatment for metastatic colorectal cancer patients (mCRC), both alone and in combination with standard of care chemotherapy, according to ... Read more

August 1, 2018

FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer

News

Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed. The first-in-human ... Read more